MCID: LKM002
MIFTS: 72

Leukemia

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Leukemia

Summaries for Leukemia

MedlinePlus : 43 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. There are different types of leukemia, including Acute lymphocytic leukemia Acute myeloid leukemia Chronic lymphocytic leukemia Chronic myeloid leukemia Leukemia can develop quickly or slowly. Chronic leukemia grows slowly. In acute leukemia, the cells are very abnormal and their number increases rapidly. Adults can get either type; children with leukemia most often have an acute type. Some leukemias can often be cured. Other types are hard to cure, but you can often control them. Treatments may include chemotherapy, radiation and stem cell transplantation. Even if symptoms disappear, you might need therapy to prevent a relapse. NIH: National Cancer Institute

MalaCards based summary : Leukemia is related to acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) and chronic myelomonocytic leukemia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia is MIR27A (MicroRNA 27a
The expression of miR-27a was inversely correlated with Multi-drug resistance (MDR) 1 expression. Transfection of exogenous miR-27a, down-regulated MDR1 and increased sensitivity of the K562-resistant cancer cells to DOX. It was found that the expression level of miR-27a was lower in patients with relapsed lymphocytic leukemia and myeloid leukemia compared to untreated patients, indicating that miR-27a might be related to clinical relapse. MDR1 is a target of miR-27a and that the putative miR-27a binding site is critical for regulating the expression of MDR1 by miR-27a.), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Arranon and Arzerra have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and b cells, and related phenotypes are Increased HDAC inhibitor resistance and cellular

Disease Ontology : 12 A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.

Wikipedia : 76 Leukemia, also spelled leukaemia, is a group of cancers that usually begin in the bone marrow and result... more...

Related Diseases for Leukemia

Diseases in the Leukemia family:

Acute Leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1368)
# Related Disease Score Top Affiliating Genes
1 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 35.1 ETV6 FLT3 RUNX1
2 chronic myelomonocytic leukemia 35.0 ETV6 FLT3 RUNX1
3 childhood leukemia 35.0 ABL1 ETV6 PBX1 RUNX1
4 acute myeloblastic leukemia with maturation 35.0 FLT3 NPM1
5 acute myeloblastic leukemia without maturation 35.0 FLT3 NPM1
6 cytogenetically normal acute myeloid leukemia 34.9 FLT3 NPM1
7 b-cell childhood acute lymphoblastic leukemia 34.6 ETV6 RUNX1
8 leukemia, acute lymphoblastic 34.5 ABL1 BCR ETV6 FLT3 MIR27A RUNX1
9 aleukemic leukemia cutis 34.5 FLT3 NPM1 RUNX1
10 b-cell adult acute lymphocytic leukemia 34.5 ABL1 PBX1
11 philadelphia-negative chronic myeloid leukemia 34.4 ABL1 BCR
12 myeloid leukemia 34.3 ABL1 BCR ETV6 FLT3 LIF MCL1
13 precursor t-cell acute lymphoblastic leukemia 34.3 ABL1 BCR ETV6 FLT3 TCL1A
14 leukemia, acute lymphoblastic 3 34.3 ABL1 BCR ETV6 FLT3 PBX1 RUNX1
15 acute myeloid leukemia with t(8;21)(q22;q22) translocation 34.3 FLT3 RUNX1
16 lymphoid leukemia 34.2 ETV6 FLT3
17 platelet disorder, familial, with associated myeloid malignancy 34.2 ETV6 RUNX1
18 acute leukemia 33.9 ETV6 FLT3 RUNX1
19 leukemia, chronic myeloid 33.9 ABL1 BCR ETV6 FLT3 HOTAIR MCL1
20 lymphoblastic leukemia 33.6 ABL1 BCR ETV6 FLT3 HOTAIR PBX1
21 acute promyelocytic leukemia 33.5 FLT3 HOTAIRM1 NEAT1 NPM1 PML RUNX1
22 acute lymphocytic leukemia 33.5 BCR CDKN2B-AS1 ETV6 MCL1 RUNX1
23 myelodysplastic syndrome 33.4 ABL1 ETV6 FLT3 MLF1 NPM1 RUNX1
24 8p11 myeloproliferative syndrome 33.4 BCR FLT3 RUNX1
25 lymphoma, non-hodgkin, familial 31.5 BCR MCL1 NPM1 TCL1A
26 mn1 31.1 ETV6 FLT3
27 alk-positive anaplastic large cell lymphoma 30.6 MCL1 NPM1
28 leukemia, acute myeloid 30.5 ABL1 BCR CDKN2B-AS1 ETV6 FLT3 HOTAIR
29 burkitt lymphoma 30.4 BCR MCL1 NEAT1 TCL1A
30 hematologic cancer 30.0 ABL1 BCR ETV6 FLT3 MCL1 NPM1
31 kidney cancer 28.4 GAS5 HOTAIR MIR27A
32 oral squamous cell carcinoma 27.6 HOTAIR MIR27A NEAT1
33 thyroid cancer, nonmedullary, 1 27.3 GAS5 HOTAIR NEAT1
34 prostate cancer 27.1 CDKN2B-AS1 GAS5 HOTAIR MCL1 MIR27A NEAT1
35 melanoma 26.9 CDKN2B-AS1 GAS5 HOTAIR HOTAIRM1 MIR27A
36 glioma 26.9 CDKN2B-AS1 GAS5 HOTAIR NEAT1
37 thyroid cancer 26.7 CDKN2B-AS1 GAS5 HOTAIR MLF1 NEAT1
38 nasopharyngeal carcinoma 26.6 CDKN2B-AS1 GAS5 HOTAIR NEAT1
39 cervical cancer 26.5 CDKN2B-AS1 GAS5 HOTAIR NEAT1
40 gastric cancer 26.5 CDKN2B-AS1 GAS5 HOTAIR MIR27A NEAT1
41 leukemia, chronic lymphocytic 12.4
42 juvenile myelomonocytic leukemia 12.3
43 hairy cell leukemia 12.3
44 megakaryocytic leukemia 12.3
45 adult t-cell leukemia 12.3
46 leukemia, acute monocytic 12.2
47 mast-cell leukemia 12.2
48 t-cell prolymphocytic leukemia 12.2
49 atypical chronic myeloid leukemia 12.2
50 prolymphocytic leukemia 12.2

Comorbidity relations with Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Leukemia:



Diseases related to Leukemia

Symptoms & Phenotypes for Leukemia

UMLS symptoms related to Leukemia:


angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased HDAC inhibitor resistance GR00115-A-0 8.62 LIF LIFR

MGI Mouse Phenotypes related to Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.2 NPM1 PBX1 PML RAF1 RUNX1 ABL1
2 hematopoietic system MP:0005397 10.15 ETV6 FLT3 LIF LIFR MCL1 NPM1
3 immune system MP:0005387 10.1 ABL1 BCR ETV6 FLT3 LIF LIFR
4 embryo MP:0005380 10.09 ABL1 ETV6 LIF LIFR MCL1 NPM1
5 endocrine/exocrine gland MP:0005379 10.06 ABL1 ETV6 FLT3 LIF LIFR MCL1
6 mortality/aging MP:0010768 9.93 FLT3 LIF LIFR MCL1 NPM1 PBX1
7 liver/biliary system MP:0005370 9.86 RAF1 RUNX1 ABL1 BCR LIF LIFR
8 neoplasm MP:0002006 9.43 ETV6 FLT3 NPM1 PML RAF1 RUNX1
9 normal MP:0002873 9.23 ABL1 BCR ETV6 MCL1 PBX1 PML

Drugs & Therapeutics for Leukemia

FDA approved drugs:

(show all 30)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
2
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
3
Blincyto 18 49 BLINATUMOMAB Amgen December 2014
4
Bosulif 18 49 BOSUTINIB MONOHYDRATE Pfizer September 2012
5
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
6
Campath 18 49 ALEMTUZUMAB Berlex Laboratories May 2001
7
Clolar 18 49 CLOFARABINE Genzyme December, 2004
8
Elitek 18 49 RASBURICASE sanofi-aventis October 2009
9
Elliotts B Solution 18 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
10
Erwinaze 18 49 asparaginase Erwinia chrysanthemi Eusa Pharma November of 2011
11
Gazyva 18 49 OBINUTUZUMAB Genentech October of 2013
12
Gleevec 18 49 IMATINIB MESYLATE Novartis May 2001
13
Iclusig 18 49 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
14
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
15
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
16
Leukine 18 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
17
Lynparza 18 49 OLAPARIB AstraZeneca December 2014
18
Marqibo 18 49 VINCRISTINE SULFATE Talon Therapeutics August 2012
19
Mylotarg 18 49 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
20
Neupogen 18 49 FILGRASTIM Amgen Approval April 1998
21
Pomalyst 18 49 POMALIDOMIDE Celgene February 2013
22
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
23
Rituxan 18 49 RITUXIMAB Biogen IDEC, Genentech November 1997
24
Sprycel 18 49 DASATINIB Bristol-Myers Squibb June 2006
25
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006
26
Synribo 18 49 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
27
Tasigna 18 49 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007
28
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
29
Trisenox 18 49 ARSENIC TRIOXIDE Cell Therapeutics September 2000
30
Zydelig 18 49 IDELALISIB Gilead July 2014

Drugs for Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 936)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
2
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
3
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
4
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
5
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1327-53-3 518740
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
7
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
8
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 58-61-7 60961
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
10
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53910-25-1 40926 439693
11
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
12
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302962-49-8 3062316
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
14
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
15
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
16
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
17
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
18
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
19
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
20
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
21
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130167-69-0
22
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
23
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
24
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 4291-63-8 20279
25
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
26
Teniposide Approved Phase 4,Phase 3,Phase 2,Not Applicable 29767-20-2 34698
27
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
28
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 59917-39-4, 53643-48-4 40839
29
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 3778-73-2 3690
30
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170729-80-3 151165 6918365
31
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 172673-20-0 219090
32
Acitretin Approved Phase 4 55079-83-9 6437841 5284513
33
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
34
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
35
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
36
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
37
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 305-03-3 2708
38
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 119413-54-6, 123948-87-8 60700
39
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 14956 5280965
40
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
41
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51264-14-3 2179
42
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
43
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
44
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
45
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
46
Oprelvekin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 145941-26-0
47
Granisetron Approved, Investigational Phase 4,Phase 2,Not Applicable 109889-09-0 3510
48
Palonosetron Approved, Investigational Phase 4,Phase 2,Not Applicable 135729-61-2, 119904-90-4, 135729-56-5 148211
49
Ketamine Approved, Vet_approved Phase 4,Phase 3 6740-88-1 3821
50
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137234-62-9 71616

Interventional clinical trials:

(show top 50) (show all 6293)
# Name Status NCT ID Phase Drugs
1 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
2 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
3 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
4 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
5 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
6 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
7 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
8 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
9 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
10 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
11 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
12 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
13 Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL Unknown status NCT01987297 Phase 4 ATRA+arsenic;ATRA+chemo
14 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
15 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
16 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
17 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
18 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
19 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
20 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
21 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
22 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
23 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
24 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
25 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
26 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
27 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
28 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
29 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
30 Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
31 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
32 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
33 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
34 Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Completed NCT00465933 Phase 4 AIDA
35 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Completed NCT01819792 Phase 4
36 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
37 PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia Completed NCT00362544 Phase 4 Ambisome
38 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
39 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
40 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
41 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
42 Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Completed NCT00408278 Phase 4 ATRA;Idarubicina;Mitoxantrone;ARA-C
43 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
44 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
45 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
46 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
47 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4 chlorambucil;cyclophosphamide;fludarabine;rituximab [MabThera]
48 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
49 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
50 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib

Search NIH Clinical Center for Leukemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia

Genetic Tests for Leukemia

Genetic tests related to Leukemia:

# Genetic test Affiliating Genes
1 Leukemia 29

Anatomical Context for Leukemia

MalaCards organs/tissues related to Leukemia:

41
Myeloid, T Cells, B Cells, Bone, Bone Marrow, Monocytes, Lung

Publications for Leukemia

Articles related to Leukemia:

(show top 50) (show all 32855)
# Title Authors Year
1
Cellular internalization and antioxidant activity of cerium oxide nanoparticles in human monocytic leukemia cells. ( 29593393 )
2018
2
Could we use parent report as a valid proxy of child report on anxiety, depression, and distress? A systematic investigation of father-mother-child triads in children successfully treated for leukemia. ( 29049860 )
2018
3
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. ( 29934061 )
2018
4
Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib. ( 29760835 )
2018
5
Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide. ( 29382244 )
2018
6
Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression. ( 29951132 )
2018
7
Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia. ( 28853218 )
2018
8
Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2. ( 29967760 )
2018
9
A rare case of a minimally secretory plasma cell leukemia with a hemorrhagic gastric plasmacytoma. ( 29892544 )
2018
10
Low Incidence of Osteonecrosis in Childhood Acute Lymphoblastic Leukemia Treated With ALL-97 and ALL-02 Study of Japan Association of Childhood Leukemia Study Group. ( 29360413 )
2018
11
Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations. ( 29449433 )
2018
12
A greater birthweight increases the risk of acute leukemias in Mexican children-experience from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia (MIGICCL). ( 29533016 )
2018
13
Indolent, waxing and waning cutaneous presentation of HTLV-1-associated adult T-cell leukemia/lymphoma in an HIV-1-positive patient. ( 29094771 )
2018
14
Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. ( 29330396 )
2018
15
Acute Lymphoblastic Leukemia Presenting as Fanconi Syndrome. ( 29515412 )
2018
16
Association between (GT)n Repeats in Heme Oxygenase-1 Gene Promoter and 3-Year Survival of Patients with Acute Leukemia: a Controlled, Cross-Sectional Study. ( 29951178 )
2018
17
Immunosuppressive monocytes (CD14<sup>+</sup>/HLA-DR<sup>low/-</sup>) increase in childhood precursor B-cell acute lymphoblastic leukemia after induction chemotherapy. ( 29429058 )
2018
18
Complete Sequences of the Human T-Cell Leukemia Virus Type 1 Proviral Genomes from Newly Established Adult T-Cell Leukemia Cell Lines in Oita Prefecture, Japan. ( 29930027 )
2018
19
Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) and all-trans retinoic acid (ATRA). ( 29963527 )
2018
20
T-cell prolymphocytic leukemia negative for surface CD3 and CD45. ( 29976781 )
2018
21
A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus. ( 29950535 )
2018
22
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome. ( 29501828 )
2018
23
Chronic subdural collection overlying an intra-axial hemorrhagic lesion in chronic myelomonocytic leukemia: special report and review of the literature. ( 29658352 )
2018
24
Evaluation by Flow Cytometry of Mature Monocyte Subpopulations for the Diagnosis and Follow-Up of Chronic Myelomonocytic Leukemia. ( 29707521 )
2018
25
Complete remission of agranulocytosis after splenectomy in a variant formA of T-cell large granular lymphocyte leukemia. ( 29963929 )
2018
26
Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <i>Blood Adv</i>. 2017;2(4):444-453. ( 29618463 )
2018
27
High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. ( 29402726 )
2018
28
Retraction notice to Inhibition of proliferation and induction of apoptosis by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide in adult T-cell leukemia cells. ( 29273235 )
2018
29
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRI+ kinase inhibitor for PDGFRI+ driving chronic eosinophilic leukemia. ( 29544149 )
2018
30
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. ( 29468060 )
2018
31
Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia. ( 29573577 )
2018
32
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. ( 29330391 )
2018
33
Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. ( 29941400 )
2018
34
Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia. ( 29431568 )
2018
35
Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis. ( 29685423 )
2018
36
Simultaneous finding of chronic lymphocytic leukemia and residual hairy cell leukemia using a lymphocyte-binding anti-CD antibody microarray. ( 29636954 )
2018
37
Posaconazole-Induced Adrenal Insufficiency in a Case of Chronic Myelomonocytic Leukemia. ( 29568655 )
2018
38
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group. ( 29794147 )
2018
39
Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. ( 29953464 )
2018
40
Genetic Mutations in a Patient with Chronic Myeloid Leukemia Showing Blast Crisis 10 Years After Presentation. ( 29970518 )
2018
41
Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report. ( 29606948 )
2018
42
Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report. ( 29105081 )
2018
43
The long non-coding RNA landscape in juvenile myelomonocytic leukemia. ( 29858388 )
2018
44
Genetic predisposition to B-cell acute lymphoblastic leukemia at 14q11.2 is mediated by a CEBPE promoter polymorphism. ( 29977016 )
2018
45
Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm. ( 29417354 )
2018
46
Successful Treatment of Pediatric Epstein-Barr Virus-positive Aggressive Natural Killer-Cell Leukemia. ( 29889803 )
2018
47
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia? ( 29402474 )
2018
48
Maternal Exposure to Pesticides, Paternal Occupation in the Army/Police Force, and CYP2D6*4 Polymorphism in the Etiology of Childhood Acute Leukemia. ( 29432309 )
2018
49
A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. ( 29452230 )
2018
50
A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34). ( 29384404 )
2018